MediTox s.r.o.


SCIENTIFIC AND COLLABORATIVE PROJECTS

EUIMMUnCoV: The European Immunotherapy Platform against 2019-NCOV

The project submitted under Horizon 2020, SC1-PHE-CORONAVIRUS-2020

The project aims at developing novel and effective gene-based vaccines activating immune response by means of in vivo electroporation mediated gene transfer (EGT).

Participating countries: Austria, Czech Republic, Denmark, Italy


MediTox s.r.o. is a member of Consortium of the project Center for Development of Original Drugs (CDOD) which in its strategic plan develops traditionally successful fields of Czech medical science and research.

The mission of CDOD project is commercialization and practical application of results of the basic research in the area of development of original drugs.

In the present time, following indications are being investigated:

  • inflammatory disease, namely ulcerous colitis and other diseases of the alimentary tract (2 projects)
  • neuro-degenerative and psychiatric diseases (1 project)
  • neoplastic diseases (5 projects)
  • treatment of obesity (1 project)

Members of the consortium:

Institute of Organi c Chemistry and Biochemistry AS CR, v.v.i.

Institute of Organi c Chemistry and Biochemistry AS CR, v.v.i.

APIGENEX s.r.o.

APIGENEX s.r.o.

Institute of Chemical Technology Prague

Institute of Chemical Technology Prague

Institute of Experimental Medicine AS CR, v.v.i.

Institute of Experimental Medicine AS CR, v.v.i.

Institute of Physiology AS CR, v.v.i.

Institute of Physiology AS CR, v.v.i.

IOCB TTO s.r.o.

IOCB TTO s.r.o.

MediTox s.r.o

MediTox s.r.o

Palacký University Olomouc

Palacký University Olomouc